Optimization of α-ketoamide based p38 inhibitors through modifications to the region that binds to the allosteric site
摘要:
We have optimized a novel series of potent p38 MAP kinase inhibitors based on an alpha-ketoamide scaffold through structure based design that due to their extended molecular architecture bind, in addition to the ATP site, to an allosteric pocket. In vitro ADME, in vivo PK and efficacy studies show these compounds to have drug-like characteristics and have resulted in the nomination of a development candidate which is currently in phase II clinical trials for the oral treatment of inflammatory conditions. (C) 2010 Elsevier Ltd. All rights reserved.
[EN] HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROARYLES UTILES EN TANT QU'INHIBITEURS DE KINASE RAF
申请人:BIOGEN IDEC INC
公开号:WO2010078408A1
公开(公告)日:2010-07-08
The present invention provides compounds of formula (I) useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf -mediated diseases.
HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
申请人:Chuaqui Claudio
公开号:US20120040951A1
公开(公告)日:2012-02-16
The present invention provides compounds of formula (I) useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.
ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND
申请人:Samsung Electronics Co., Ltd.
公开号:EP3750900A1
公开(公告)日:2020-12-16
Provided are an organometallic compound represented by Formula 1, an organic light-emitting device including the organometallic compound, and a diagnostic composition including the organometallic compound.
M1(L11)n11(L12)n12
L11 in Formula 1 is a ligand represented by Formula 1-1, and other substituents are the same as described in the detailed description of the specification: